JCI The Journal of Clinical Investigation

ATP11B mediates platinum resistance in ovarian cancer

Myrthala Moreno-Smith, … , Gabriel Lopez-Berestein, Anil K. Sood

J Clin Invest. 2013;123(12):5411-5411. https://doi.org/10.1172/JCI73904.

Corrigendum

Original citation: J Clin Invest. 2013;123(5):2119–2130. doi:10.1172/JCI65425. Citation for this corrigendum: J Clin Invest. 2013;123(12):5411. doi:10.1172/JCI73904. The legend for Figure 5 did not disclose that the images presented in part A were duplicated as the no treatment control for the cisplatin experiment shown in parts D and E. The authors wish to add the correction below to the legend for Figure 5. The merged immunofluorescence images showing colocalization of ATP11B and STX6 in A2780-PAR and A2780-CP20 cells in A are shown again in D and E to demonstrate localization of ATP11B and STX6 in the absence of cisplatin in A2780-PAR and A2780-CP20 cells. The authors regret the error.

Corrigendum

ATP11B mediates platinum resistance in ovarian cancer

Myrthala Moreno-Smith, J.B. Halder, Paul S. Meltzer, Tamas A. Gonda, Lingegowda S. Mangala, Rajesha Rupaimoole, Chunhua Lu, Archana S. Nagaraja, Kshipra M. Gharpure, Yu Kang, Cristian Rodriguez-Aguayo, Pablo E. Vivas-Mejia, Behrouz Zand, Rosemarie Schmandt, Hua Wang, Robert R. Langley, Nicholas B. Jennings, Cristina Ivan, Jeremy E. Coffin, Guillermo N. Armaiz, Justin Bottsford-Miller, Sang Bae Kim, Margaret S. Halleck, Mary J.C. Hendrix, William Bornman, Menashe Bar-Eli, Ju-Seog Lee, Zahid H. Siddik, Gabriel Lopez-Berestein, and Anil K. Sood

Original citation: *J Clin Invest*. 2013;123(5):2119–2130. doi:10.1172/JCI65425.

Citation for this corrigendum: *J Clin Invest*. 2013;123(12):5411. doi:10.1172/JCI73904.

The legend for Figure 5 did not disclose that the images presented in part A were duplicated as the no treatment control for the cisplatin experiment shown in parts D and E. The authors wish to add the correction below to the legend for Figure 5.

The merged immunofluorescence images showing colocalization of ATP11B and STX6 in A2780-PAR and A2780-CP20 cells in **A** are shown again in **D** and **E** to demonstrate localization of ATP11B and STX6 in the absence of cisplatin in A2780-PAR and A2780-CP20 cells.

The authors regret the error.

Corrigendum

Sema3E–Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice

Andrea Casazza, Veronica Finisguerra, Lorena Capparuccia, Andrea Camperi, Jakub M. Swiercz, Sabrina Rizzolio, Charlotte Rolny, Claus Christensen, Andrea Bertotti, Ivana Sarotto, Mauro Risio, Livio Trusolino, Jurgen Weitz, Martin Schneider, Massimilano Mazzone, Paolo M. Comoglio, and Luca Tamagnone

Original citation: *J Clin Invest*. 2010;120(8):2684–2698. doi:10.1172/JCI42118.

Citation for this corrigendum: *J Clin Invest*. 2013;123(12):5411. doi:10.1172/JCI74037.

During the assembly of Figure 2G of this manuscript, the p61 band in the shRNA Sema3E lane of the anti-Sema3E blot was intentionally skewed to appear straightened. The original, unadjusted Sema3E blot is shown in the corrected figure panel below. The authors were also able to demonstrate comparable results, which were provided to the journal, for Sema3E knockdown in 4T1 cells in replicate experiments.

The authors regret the error.